PIVYA® (pivmecillinam) tablets is a penicillin class antibiotic for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible bacteria.

This website is intended for US healthcare professionals only.

HCP Resources Hero

Resources

Download Materials and Explore Clinical Evidence

Download Our Brochures

Download our brochures for more information on how PIVYA can help your patients get relief from uncomplicated UTIs.

For Your Patients

Patient Brochure

For Healthcare Professionals

HCP Brochure

Get More Information about PIVYA

Explore clinical publications on pivmecillinam, antibiotic resistance, and uncomplicated urinary tract infections. Download resources for your practice and your patients.

Clinical Evidence and Safety

  • Lodise TP, Das AF, Frimodt-Møller N, et al. Pivmecillinam for treatment of uncomplicated urinary tract infection: new efficacy analysis. Clin Infect Dis. 2025;81(5):e285-e293. doi:10.1093/cid/ciaf280.
  • Kaye KS, Santerre Henriksen A, Sommer M, Frimodt-Møller N. Safety and tolerability of pivmecillinam during more than four decades of clinical experience: a systematic review. Clin Infect Dis. 2025;80(2):280-299. doi:10.1093/cid/ciae621.
  • Hawkins BK, Ding H, Harriott MM, Wang JL. New perspectives on antimicrobial agents: pivmecillinam. Antimicrob Agents Chemother. 2025;69(8):e0182424. doi:10.1128/aac.01824-24.
  • Vik I, Bollestad M, Grude N, et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—a double-blind, randomized non-inferiority trial. PLoS Med. 2018;15(5):e1002569. doi:10.1371/journal.pmed.1002569.

Antibiotic Resistance and Mecillinam Activity

  • Lodise TP, Kaye KS, Santerre Henriksen A, Kahlmeter G. Review of the in vitro microbiological activity of mecillinam against common uropathogens in uncomplicated urinary tract infection: focus on resistant pathogens. Open Forum Infect Dis. 2024;11(6):ofae296. doi:10.1093/ofid/ofae296.
  • Hawser S, Morrissey I, Kothari N, Monti F, Santerre Henriksen A. Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics. J Glob Antimicrob Resist. 2024;39:137-143. doi:10.1016/j.jgar.2024.08.013.
  • Kaye KS, Gupta V, Mulgirigama A, et al. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management. Clin Infect Dis. 2021;73(11):1992-1999. doi:10.1093/cid/ciab560.

Recurrent UTIs and Patient Perspectives

  • Ackerman AL, et al. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 2026;215:3-12.
  • Fromer DL, Cheng WY, Gao C, et al. Likelihood of antimicrobial resistance in urinary E. coli isolates among US female patients with recurrent versus non-recurrent uUTI. Urology. 2024;190:1-10. doi:10.1016/j.urology.2024.02.047.
  • Advani SD, Thaden JT, Perez R, Stair SL, Lee UJ, Siddiqui NY. State-of-the-art review: recurrent uncomplicated urinary tract infections in women. Clin Infect Dis. 2025;80(3):e31-e42. doi:10.1093/cid/ciae653.
  • Lelie-van der Zande R, Koster ES, Teichert M, Bouvy ML. Womens’ self-management skills for prevention and treatment of recurring urinary tract infection. Int J Clin Pract. 2021;75(8):e14289. doi:10.1111/ijcp.14289.

Treatment Guidelines

  • Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257.
  • European Association of Urology. EAU guidelines on urological infections. 2026 edition. EAU Guidelines Office; 2026.
  • IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.

Help Your Patients Save on Their Prescription for PIVYA

Most eligible commercially insured patients pay between $0 and $15 using the PIVYA copay savings card.

PIVYA Copay Card

Request samples for your office

Click the button below to fill out an online form to receive a free sample of PIVYA.

In compliance with the Prescription Drug Marketing Act regulations, incomplete request forms cannot be processed and samples will not be delivered.